Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | ALKBH3 | Q96Q83 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879048 | 0.92 | HTR2B (0.41) | NPY5RHTR2BMAPTTRPC3SUV39H2 | |
| SCHEMBL2886433 | 0.84 | NPY5R (0.48) | NPY5RALKBH3HTR2BLMNAMAPT | |
| SCHEMBL2886429 | 0.76 | TRPC3 (0.45) | NPY5RHTR2BLMNAMAPTTRPC3 | |
| SCHEMBL2878853 | 0.71 | NPY5R (0.52) | NPY5RALKBH3HTR2BEGLN1LMNA | |
| SCHEMBL2885065 | 0.69 | NPY5R (0.46) | NPY5RALKBH3HTR2BUSP30 | |
| SCHEMBL4171714 | 0.69 | CA1 (0.55) | — | |
| SCHEMBL2884445 | 0.68 | NPY5R (0.42) | NPY5RLMNATRPC3TP53 | |
| SCHEMBL2881817 | 0.67 | NPY5R (0.46) | NPY5RALKBH3USP30 | |
| SCHEMBL2879397 | 0.67 | NPY5R (0.52) | NPY5RHTR2BLMNAMAPTUSP30 | |
| SCHEMBL2884212 | 0.67 | NPY5R (0.52) | NPY5RHTR2BLMNAMAPTUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | claimed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | claimed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | claimed |
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | NPY5R 3/4885ALKBH3 2120/4885HTR2B 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.